Rochester Medical Corporation

Rochester Medical — Shareholder Meeting (February 2009)

26 slides from Rochester Medical's shareholder meeting presentation, Feb 4, 2009

  1. Slide 1: Rochester Medical Corporation 2009 Annual Meeting

    Slide 1: Rochester Medical Corporation 2009 Annual Meeting

    Rochester Medical Corporation 2009 Annual Meeting

  2. Slide 2: Forward Looking Statements

    Slide 2: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic r

  3. Slide 3: Outline

    Slide 3: Outline

    Outline Corporate Overview Markets Products Financial Highlights Opportunities Potential FemSoft Opportunity Q&A

  4. Slide 4: Company Facts

    Slide 4: Company Facts

    Company Facts Develop, Manufacture and Sell Disposable Incontinence and Bladder Drainage Devices Three Major Product Categories-Soon to be Four Rochester Medical Brand Sold in Over 75 Countries Focus on North America and Europe Private Label Sales to Major Medical Device Companies 28 Acres, Stewartv

  5. Slide 5: Sales - Brand Focused Growth, Private Label Stability

    Slide 5: Sales - Brand Focused Growth, Private Label Stability

    Sales -Brand Focused Growth Private Label "Stability" F03 F04 F05 F06 F07 F08 RM Branded 6291000 6551000 7351000 10797000 19226000 23848000 Private Label 3081627 2427665 8591000 10834000 13437000 11344000

  6. Slide 6: Market Opportunity - Today

    Slide 6: Market Opportunity - Today

    Market Opportunity - Today Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $70 $100 $300 $470 Foley/Urological Catheter $400 $50 $70 $520 TOTALS $520 $168 $430 $1,118 ($ in millions) Extended Care Extended Care AcuteCare

  7. Slide 7: Market Opportunity - Future

    Slide 7: Market Opportunity - Future

    Market Opportunity -Future Products/Markets U.S. U.K. Rest of Europe Total Male External Catheter $50 $18 $60 $128 Intermittent $400 $100 $300 $800 Foley/Urological Catheter $400 $50 $70 $520 TOTALS $520 $168 $430 $1,448 ($ in millions) Extended Care Extended Care AcuteCare

  8. Slide 8: Product Superiority: MEC (male external catheters)

    Slide 8: Product Superiority: MEC (male external catheters)

    Product Superiority MEC (male external catheters) MEC (male external catheters) MEC (male external catheters)

  9. Slide 9: Product Superiority: MEC (male external catheters)

    Slide 9: Product Superiority: MEC (male external catheters)

    Product Superiority MEC (male external catheters) All Silicone - non-latex Breathable Odorless Proven Quality Largest Global Manufacturer 4 Distinct models Generational Product Improvement in R&D Pipeline

  10. Slide 10: Product Superiority: Intermittent Catheters - Magic3

    Slide 10: Product Superiority: Intermittent Catheters - Magic3

    Product Superiority Intermittent Catheters-Magic3TM Intermittent Catheters-Magic3TM Intermittent Catheters-Magic3TM

  11. Slide 11: Product Superiority: Intermittent Catheters

    Slide 11: Product Superiority: Intermittent Catheters

    Product Superiority Intermittent Catheters The only 100% Silicone Intermittent- non-PVC Softness Eyes No leachables No Disposal issues Proprietary Hydrophilic technology The only Intermittent Antibacterial technology The only Silicone / Hydro / Antibacterial combination Major product enhancement jus

  12. Slide 12: Product Superiority: Foley Catheters

    Slide 12: Product Superiority: Foley Catheters

    Product Superiority Foley Catheters Foley Catheters Foley Catheters

  13. Slide 13: Enhanced Silicone Catheter

    Slide 13: Enhanced Silicone Catheter

    Enhanced” sone Catater ee - ™ Pree

  14. Slide 14: Product Superiority: Foley Catheters

    Slide 14: Product Superiority: Foley Catheters

    Product Superiority Foley Catheters All Silicone - non-latex Patented integrated balloon system Patented drug elution infection control system The only Foley catheter Indicated for infection control The only Foley catheter clinically proven to significantly reduce infection versus silicone control c

  15. Slide 15: Domestic Sales - Rochester Medical Brand

    Slide 15: Domestic Sales - Rochester Medical Brand

    Domestic Sales - Rochester Medical(r) Brand Field Organization Rochester Extensive Provider Distribution Network Effective, well positioned Sales Force Capable, Aggressive and Creative Extended and Acute Care Focus Rochester Medical Brand Only Expect Solid Growth ROCM Homecare Personnel ROCM Sales P

  16. Slide 16: Domestic Sales: Selling MECs, U.S. Private Label

    Slide 16: Domestic Sales: Selling MECs, U.S. Private Label

    Domestic Sales Selling MECs Valuable, Non-strategic Business Serviced by Centralized Personnel U.S. Private Label Customers

  17. Slide 17: UK Sales Territories

    Slide 17: UK Sales Territories

    UK Sales Territories Scotland 1 Scotland 2 (part time) North North West South West South North East East Anglia North Thames West Midlands Location of nurses

  18. Slide 18: International Sales

    Slide 18: International Sales

    International Sales Selling our MECs and Foleys Private Label Customers

  19. Slide 19: Financials

    Slide 19: Financials

    Financials Sales F2008 $35.2M...68% Branded Annualized Branded Growth 25-30% Q1-09 $8.4 Margin Near 50% 60% Achievable with volume growth Currently pressured by exchange rates Operating Expenses Major investment in sales and marketing infrastructure Fairly flat in the near term Favorable impact from

  20. Slide 20: Opportunities

    Slide 20: Opportunities

    Opportunities 3 current Major branded growth initiatives UK market (all 3 product lines) Expansion to mainland initiated Hydrosil Discreet (Magic Technology) just introduced US Acute Care market GPO contracts New Reimbursement guidelines Infection Control Focus New Product Enhancements in April 2009

  21. Slide 21: Intermittent Catheter Reimbursement Change

    Slide 21: Intermittent Catheter Reimbursement Change

    Intermittent Catheter Reimbursement Change- 200/mo. instead of 4/mo. Change is creating opportunity for National DTC approach for incontinence devices-similar to Diabetic Supplies and "Scooter" Ads. DTC campaign has begun but is off to a slower than expected start DTC aproach potentially opens up si

  22. Slide 22: FemSoft

    Slide 22: FemSoft

    FemSoft(r)

  23. Slide 23: U.S. Theoretical FemSoft Potential

    Slide 23: U.S. Theoretical FemSoft Potential

    U.S. Theoretical FemSoft Potential 12,000,000 Incontinent Females 5% Penetration = 600,000 Users At Current Reimbursement Assuming 2 devices per day = $937,320,000 Rochester Medical = $468,660,000 Engaged in Preliminary Discussion with Distributors for possible National Campaign * Also working towar

  24. Slide 24: Summary

    Slide 24: Summary

    Summary Excellent Opportunities Rochester Medical in strong position to achieve success Superior, advanced products and technology New market dynamics (reimbursement policies) New focus on infection control Core structure in place Magic Intermittents just introduced worldwide New Enhanced Foley intr

  25. Slide 25: Forward Looking Statements

    Slide 25: Forward Looking Statements

    Forward Looking Statements This presentation contains forward-looking statements that involve risks and uncertainties, including the uncertainty of estimated revenues and profits, as well as the uncertainty of market acceptance of new product introductions, the uncertainty of gaining new strategic r

  26. Slide 26: Rochester Medical Corporation

    Slide 26: Rochester Medical Corporation

    Rochester Medical Corporation

Source: SEC EDGAR · 8-K filed Feb 4, 2009

More decks from Rochester Medical Corporation